The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
CaMKII inhibitors: from research tools to therapeutic agents
Open accessAbstract
The cardiac field has benefited from the availability of several CaMKII inhibitors serving as research tools to test putative CaMKII pathways associated with cardiovascular physiology and pathophysiology. Successful demonstrations of its critical pathophysiological roles have elevated CaMKII as a key target in heart failure, arrhythmia, and other forms of heart disease. This has caught the attention of the pharmaceutical industry, which is now racing to develop CaMKII inhibitors as safe and effective therapeutic agents. While the first generation of CaMKII inhibitor development is focused on blocking its activity based on ATP binding to its catalytic site, future inhibitors can also target sites affecting its regulation by Ca(2+)/CaM or translocation to some of its protein substrates. The recent availability of crystal structures of the kinase in the autoinhibited and activated state, and of the dodecameric holoenzyme, provides insights into the mechanism of action of existing inhibitors. It is also accelerating the design and development of better pharmacological inhibitors. This review examines the structure of the kinase and suggests possible sites for its inhibition. It also analyzes the uses and limitations of current research tools. Development of new inhibitors will enable preclinical proof of concept tests and clinical development of successful lead compounds, as well as improved research tools to more accurately examine and extend knowledge of the role of CaMKII in cardiac health and disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanson, P. I., Meyer, T., Stryer, L., & Schulman, H. (1994) · Neuron · doi:10.1016/0896-6273(94)90306-9 · Cited by 500
Self-citationStructure of the Autoinhibited Kinase Domain of CaMKII and SAXS Analysis of the Holoenzyme
Rosenberg, O. S., Deindl, S., Sung, R.-J., Nairn, A. C., & Kuriyan, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.029 · Cited by 333
Rellos, P., Pike, A. C. W., Niesen, F. H., Salah, E., Lee, W. H., von Delft, F., & Knapp, S. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000426 · Cited by 279 · cited 3×
“The activated state seen in a crystal structure of the kinase domain with the regulatory segment displaced from the kinase domain and bound to Ca2+/CaM sheds light on the process of activation by CaM (Rellos et al., 2010).”
BackgroundCharacterization of a calmodulin kinase II inhibitor protein in brain
Chang, B. H., Mukherji, S., & Soderling, T. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10890 · Cited by 227
Rich, R. C., & Schulman, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28424 · Cited by 162
Self-citationBuard, I., Coultrap, S. J., Freund, R. K., Lee, Y.-S., Dell'Acqua, M. L., Silva, A. J., & Bayer, K. U. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1469-10.2010 · Cited by 160
Intersubunit capture of regulatory segments is a component of cooperative CaMKII activation
Chao, L. H., Pellicena, P., Deindl, S., Barclay, L. A., Schulman, H., & Kuriyan, J. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1751 · Cited by 119
Self-citationChang, B. H., Mukherji, S., & Soderling, T. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00520-0 · Cited by 95
Cited by
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Mechanotransduction in Cardiac Hypertrophy and Failure
Lyon, R. C., Zanella, F., Omens, J. H., & Sheikh, F. (2015) · Circulation Research · doi:10.1161/circresaha.116.304937 · Cited by 344
CaM Kinase: Still Inspiring at 40
Bayer, K. U., & Schulman, H. (2019) · Neuron · doi:10.1016/j.neuron.2019.05.033 · Cited by 326
Self-citationTargeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles
Bonora, M., Wieckowski, M. R., Sinclair, D. A., Kroemer, G., Pinton, P., & Galluzzi, L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0074-0 · Cited by 294
Nicoll, R. A., & Schulman, H. (2023) · Physiological Reviews · doi:10.1152/physrev.00034.2022 · Cited by 126
“Unfortunately, the strong nonspeci fi c effects of AntCN27 and tatCN21 during the application (see above) precluded directly recording the reversal of LTP.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Pellicena, P., & Schulman, H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 5
- Pages
- 21-21
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2160560939
- Cited by
- 234
- References
- 8
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CaMKII inhibitors: from research tools to therapeutic agents. https://app.cochat.ai/papers/10.3389/fphar.2014.00021
- The paper
- Pellicena, P., & Schulman, H. (2014). CaMKII inhibitors: from research tools to therapeutic agents. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2014.00021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.